Clinical practice guidelines on image-guided thermal ablation of primary and metastatic lung tumors (2022 edition)

Ye, Xin; Fan, Weijun; Wang, Zhongmin; Wang, Junjie; Wang, Hui; Niu, Lizhi; Fang, Yong; Gu, Shanzhi; Liu, Lingxiao; Liu, Baodong; Zhuang, Yibo; Wei, Zhigang; Li, Xiao; Li, Xiaoguang; Li, Yuliang; Li, Chunhai; Yang, Xia; Yang, Wuwei; Yang, Po Song; Lin, Zhengyu; Meng, Zhefeng; Hu, Kaiwen; Liu, Chen; Huang, Yong; Huang, Guanghui; Huang, Kai-Ping; Peng, Zhongmin; Han, Yue; Jin, Yong; Lei, Guangyan; Zhai, Bo; Li, Hailiang; Pan, Jie; Filippiadis, Dimitris; Kelekis, Alexis; Pua, Uei; Futácsi, Balázs; Yumchinserchin, N; Iezzi, Roberto; Tang, Alex; Roy, Shuvro H

doi:10.4103/jcrt.jcrt_880_22

Cited by 30 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer is the leading cause of death from malignant tumors worldwide (9). NSCLC is the most common pathological tissue type, which accounts for about 80% of all types of lung cancers (10). The 5-year survival rate after surgical resection of lung cancer in the early stage is about 29%-77%.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization for refractory non-small-cell lung cancer and its impact on quality of life: A multicenter prospective study

Zhao

Liu²,

Qin

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThis study aimed to prospectively observe the efficacy and safety of CalliSpheres drug-eluting beads bronchial arterial chemoembolization (DEB-BACE) for refractory non-small-cell lung cancer (NSCLC).MethodsThe interventional therapy plan was as follows: 300–500 μm CalliSpheres drug-loaded microspheres were loaded with epirubicin, and then slow embolization of tumor supplying artery was performed after microcatheter superselection. Chest enhanced computed tomography and related hematological examination were reviewed after 2 months of DEB-BACE, and the tumor response after the first interventional therapy was evaluated using modified response evaluation criteria in solid tumors. The overall survival (OS) of patients was determined, and the quality of life and the incidence rate of adverse reactions were observed.ResultsFrom January 2019 to January 2021, 43 patients with refractory NSCLC were enrolled. The patients were followed up until June 2022. All 43 patients underwent DEB-BACE 1.79 ± 0.69 times on average. The 3-, 6-, 12-, and 24-month survival rates were 100%, 86.0%, 41.9%, and 11.8%, respectively. The median OS was 11.5 months. After the first interventional treatment, cough and wheezing significantly improved in 31 patients, hemoptysis was effectively controlled in 12 patients, and superior vena cava compression disappeared in 2 patients after 2 times of treatment. The general health status of the patients after treatment significantly improved compared with that before treatment, including the improvement in physical and emotional functions. Fatigue, nausea and vomiting, dyspnea, and insomnia improved significantly after treatment. No serious adverse events, such as spinal cord injury and cerebral embolism, were observed during the perioperative period. The main adverse reaction after DEB-BACE was chest pain (13/43, grade 1) followed by fever (10/43, grade 1–2), which was significantly relieved within 3–5 days after symptomatic treatment. Other adverse reactions included irritating cough, nausea and vomiting, and bone marrow suppression, and the incidence was less than 20%.ConclusionsDEB-BACE was effective and safe in treating refractory NSCLC, which could significantly improve patients’ quality of life and was worthy of clinical promotion and application.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization for refractory non-small-cell lung cancer and its impact on quality of life: A multicenter prospective study

Zhao

Liu²,

Qin

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…MWA was performed after the cold circulating pipes and pump were connected to the MWA antenna and machine. The procedure was terminated when the post-ablation ground-glass opacity (GGO) surpassed the GTR by at least 5 mm [ 5 , 16 ]. After this, the target tissue is defined as a post-ablation tumor zone (PTZ) [ 5 ].…”

Section: Methodsmentioning

confidence: 99%

“…The procedure was terminated when the post-ablation ground-glass opacity (GGO) surpassed the GTR by at least 5 mm [ 5 , 16 ]. After this, the target tissue is defined as a post-ablation tumor zone (PTZ) [ 5 ]. After the procedure, the antenna was removed, and the wound was locally disinfected and bandaged.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical outcomes of percutaneous microwave ablation for pulmonary oligometastases from hepatocellular carcinoma: a retrospective, multicenter study

Wang,

Wei,

Wang

et al. 2024

Cancer Imaging

Self Cite

View full text Add to dashboard Cite

Background Pulmonary oligometastases are common in hepatocellular carcinoma (HCC), however, the existing therapeutic options have several limitations. This study aimed to assess the safety and efficacy of microwave ablation (MWA) in the treatment of HCC-originating pulmonary oligometastases. Methods A total of 83 patients, comprising 73 males and 10 females with a median age of 57 years, who had pulmonary oligometastases from HCC, underwent MWA treatment at four different medical institutions. Inclusion criteria for patients involved having primary HCC under control and having less than three oligometastases with a maximum diameter of ≤ 5 cm in the unilateral lung or less than five oligometastases with a maximum diameter of ≤ 3 cm in the bilateral lung. A total of 147 tumors were treated with MWA over 116 sessions. The primary endpoints assessed included technical success, treatment efficacy, and local progression rate, while secondary endpoints encompassed complications, clinical outcomes, overall survival (OS), local progression-free survival (LPFS), and prognostic factors. Results The technical success rate for MWA was 100% (116/116 sessions), and the treatment efficacy rate was 82.3% (121/147 tumors). Six months after MWA, the local progression rate was 23.1% (18/147 tumors). Complications were observed in 10.3% (major) and 47.4% (minor) of the 116 sessions, with no cases of ablation-related deaths. The median follow-up period was 21.6 months (range: 5.7–87.8 months). Median OS was 22.0 months, and the 1-, 2-, and 3-year OS rates were 82.6%, 44.5%, and 25.2%, respectively. Median LPFS was 8.5 months. Multivariate Cox regression analysis identified α-fetoprotein (AFP) levels during initial diagnosis and the number of oligometastases as potential independent prognostic factors for OS (p = 0.017 and 0.045, respectively). Conclusion Percutaneous MWA is a safe and effective treatment modality for pulmonary oligometastases originating from HCC.

show abstract

“…For early-stage NSCLC and for some lung metastases, radical surgery usually represents the main treatment method; in unsurgical patients, percutaneous image-guided thermal ablation, such as radiofrequency ablation (RFA), microwave ablation (MWA) and cryoablation, has been increasingly applied as a safe, cost- effective, and precise minimally invasive alternative treatment methods ( 5 ).…”

mentioning

confidence: 99%

Editorial: Local ablative therapies for the management of lung cancer

Wei

Iezzi²,

Ye³

2023

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Clinical practice guidelines on image-guided thermal ablation of primary and metastatic lung tumors (2022 edition)

Cited by 30 publications

References 0 publications

Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization for refractory non-small-cell lung cancer and its impact on quality of life: A multicenter prospective study

Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization for refractory non-small-cell lung cancer and its impact on quality of life: A multicenter prospective study

Clinical outcomes of percutaneous microwave ablation for pulmonary oligometastases from hepatocellular carcinoma: a retrospective, multicenter study

Editorial: Local ablative therapies for the management of lung cancer

Contact Info

Product

Resources

About